Liu H, Li W, Zhang W, Sun S, Chen C
Endocr Rev. 2022; 44(3):393-416.
PMID: 36412275
PMC: 10166268.
DOI: 10.1210/endrev/bnac030.
Cruz-Loya M, Chu B, Jonklaas J, Schneider D, DiStefano 3rd J
Front Endocrinol (Lausanne). 2022; 13:888429.
PMID: 35909562
PMC: 9330449.
DOI: 10.3389/fendo.2022.888429.
Bjerkreim B, Hammerstad S, Gulseth H, Berg T, Omdal L, Lee-Odegard S
Front Endocrinol (Lausanne). 2022; 13:816566.
PMID: 35273566
PMC: 8902821.
DOI: 10.3389/fendo.2022.816566.
Klubo-Gwiezdzinska J, Wartofsky L
Pol Arch Intern Med. 2022; 132(3).
PMID: 35243857
PMC: 9478900.
DOI: 10.20452/pamw.16222.
Planck T, Lantz M, Perros P, Papini E, Attanasio R, Nagy E
Front Endocrinol (Lausanne). 2021; 12:795111.
PMID: 34938274
PMC: 8687360.
DOI: 10.3389/fendo.2021.795111.
Optimal Thyroid Hormone Replacement.
Jonklaas J
Endocr Rev. 2021; 43(2):366-404.
PMID: 34543420
PMC: 8905334.
DOI: 10.1210/endrev/bnab031.
Benefits and Harms of Levothyroxine/L-Triiodothyronine Versus Levothyroxine Monotherapy for Adult Patients with Hypothyroidism: Systematic Review and Meta-Analysis.
Millan-Alanis J, Gonzalez-Gonzalez J, Flores-Rodriguez A, Ospina N, Maraka S, Moreno-Pena P
Thyroid. 2021; 31(11):1613-1625.
PMID: 34340589
PMC: 8917901.
DOI: 10.1089/thy.2021.0270.
Individualized Therapy for Hypothyroidism: Is T4 Enough for Everyone?.
Ettleson M, Bianco A
J Clin Endocrinol Metab. 2020; 105(9).
PMID: 32614450
PMC: 7382053.
DOI: 10.1210/clinem/dgaa430.
Predicting Optimal Combination LT4 + LT3 Therapy for Hypothyroidism Based on Residual Thyroid Function.
DiStefano 3rd J, Jonklaas J
Front Endocrinol (Lausanne). 2019; 10:746.
PMID: 31803137
PMC: 6873785.
DOI: 10.3389/fendo.2019.00746.
Individualised requirements for optimum treatment of hypothyroidism: complex needs, limited options.
Hoermann R, Midgley J, Larisch R, Dietrich J
Drugs Context. 2019; 8:212597.
PMID: 31516533
PMC: 6726361.
DOI: 10.7573/dic.212597.
Time for a reassessment of the treatment of hypothyroidism.
Midgley J, Toft A, Larisch R, Dietrich J, Hoermann R
BMC Endocr Disord. 2019; 19(1):37.
PMID: 30999905
PMC: 6471951.
DOI: 10.1186/s12902-019-0365-4.
Prescribing Therapy for Hypothyroidism: Influence of Physician Characteristics.
Jonklaas J, Tefera E, Shara N
Thyroid. 2018; 29(1):44-52.
PMID: 30375273
PMC: 6352496.
DOI: 10.1089/thy.2018.0369.
Physician Choice of Hypothyroidism Therapy: Influence of Patient Characteristics.
Jonklaas J, Tefera E, Shara N
Thyroid. 2018; 28(11):1416-1424.
PMID: 30289349
PMC: 6247977.
DOI: 10.1089/thy.2018.0325.
Effects of Long-Term Combination LT4 and LT3 Therapy for Improving Hypothyroidism and Overall Quality of Life.
Tariq A, Wert Y, Cheriyath P, Joshi R
South Med J. 2018; 111(6):363-369.
PMID: 29863229
PMC: 5965938.
DOI: 10.14423/SMJ.0000000000000823.
Current evidence for the treatment of hypothyroidism with levothyroxine/levotriiodothyronine combination therapy versus levothyroxine monotherapy.
Hennessey J, Espaillat R
Int J Clin Pract. 2018; 72(2).
PMID: 29381251
PMC: 5873391.
DOI: 10.1111/ijcp.13062.
Management of hypothyroidism with combination thyroxine (T4) and triiodothyronine (T3) hormone replacement in clinical practice: a review of suggested guidance.
Dayan C, Panicker V
Thyroid Res. 2018; 11:1.
PMID: 29375671
PMC: 5772692.
DOI: 10.1186/s13044-018-0045-x.
Persistent hypothyroid symptoms in a patient with a normal thyroid stimulating hormone level.
Jonklaas J
Curr Opin Endocrinol Diabetes Obes. 2017; 24(5):356-363.
PMID: 28632526
PMC: 5824691.
DOI: 10.1097/MED.0000000000000355.
Severe TSH Elevation and Pituitary Enlargement After Changing Thyroid Replacement to Compounded T4/T3 Therapy.
Pappy 2nd A, Oyesiku N, Ioachimescu A
J Investig Med High Impact Case Rep. 2016; 4(3):2324709616661834.
PMID: 27540557
PMC: 4973410.
DOI: 10.1177/2324709616661834.
Recommendations for treatment of hypothyroidism with levothyroxine and levotriiodothyronine: a 2016 position statement of the Italian Society of Endocrinology and the Italian Thyroid Association.
Biondi B, Bartalena L, Chiovato L, Lenzi A, Mariotti S, Pacini F
J Endocrinol Invest. 2016; 39(12):1465-1474.
PMID: 27473077
DOI: 10.1007/s40618-016-0511-z.
Daily Administration of Short-Acting Liothyronine Is Associated with Significant Triiodothyronine Excursions and Fails to Alter Thyroid-Responsive Parameters.
Jonklaas J, Burman K
Thyroid. 2016; 26(6):770-8.
PMID: 27030088
PMC: 4913511.
DOI: 10.1089/thy.2015.0629.